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MD2 activation by direct AGE interaction drives
inﬂammatory diabetic cardiomyopathy
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Yi Wang1,2,4 ✉, Wu Luo2,4, Jibo Han1,2,4, Zia A. Khan2,3, Qilu Fang2, Yiyi Jin2, Xuemei Chen2, Yali Zhang2,
Meihong Wang2, Jianchang Qian2, Weijian Huang1, Hazel Lum2, Gaojun Wu1 & Guang Liang 1,2 ✉

Hyperglycemia activates toll-like receptor 4 (TLR4) to induce inﬂammation in diabetic cardiomyopathy (DCM). However, the mechanisms of TLR4 activation remain unclear. Here we
examine the role of myeloid differentiation 2 (MD2), a co-receptor of TLR4, in high glucose
(HG)- and diabetes-induced inﬂammatory cardiomyopathy. We show increased MD2 in
heart tissues of diabetic mice and serum of human diabetic subjects. MD2 deﬁciency in mice
inhibits TLR4 pathway activation, which correlates with reduced myocardial remodeling and
improved cardiac function. Mechanistically, we show that HG induces extracellular advanced
glycation end products (AGEs), which bind directly to MD2, leading to formation of AGEsMD2-TLR4 complex and initiation of pro-inﬂammatory pathways. We further detect elevated
AGE-MD2 complexes in heart tissues and serum of diabetic mice and human subjects with
DCM. In summary, we uncover a new mechanism of HG-induced inﬂammatory responses
and myocardial injury, in which AGE products directly bind MD2 to drive inﬂammatory DCM.
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iabetic cardiomyopathy (DCM) is a signiﬁcant cause of
morbidity and mortality in diabetic patients1. Multiple
factors contribute to the development of DCM1,2, with
myocardial inﬂammation representing an early event3–5. Much
evidence documents a causal relation between hyperglycemia and
inﬂammation in diabetes, appearing to engage both direct and
indirect regulation. High levels of glucose (HG) can directly
promote inﬂammatory activities such as increased production of
pro-inﬂammatory cytokines6–8, in a wide range of cell types.
However, the precise pathway(s) by which glucose initiates the
pro-inﬂammatory cascades remain unclear.
Chronic inﬂammation in diabetes is believed to be linked to the
activation of toll-like receptor 4 (TLR4), a component of the
innate immune system9. TLR4 forms a cell-surface dimer with its
co-receptor, myeloid differentiation factor 2 (MD2) to function as
a recognition receptor for lipopolysaccharide (LPS). Upon LPS
binding to MD2, LPS-MD2-TLR4 complex dimerizes and recruits
myeloid differentiation primary response-88 (MyD88) and activates mitogen-activated protein kinases (MAPKs) and nuclear
factor-kappa B (NFκB), which upregulate inﬂammatory cytokines10. In vitro studies show that HG activates TLR4 in myocytes11, monocytes12, endothelial cell13, and kidney epithelial13,14
and mesangial cells15. In addition, monocytes in human diabetic
subjects show elevated levels of MD2 and TLR416. Diabetic mice
and rats also show increased TLR4 levels in heart tissues17,18.
Predictably, inhibition of TLR4 confers signiﬁcant protection
against cardiac remodeling and dysfunction in diabetic animals19–21. It is interesting to note that TLR4 can be activated by
multiple endogenous ligands present in the diabetic milieu22. Our
previous study showed that saturated fatty acids are able to
directly bind MD2 and activate the MD2-TLR4 signaling pathway23. MD2 also mediates angiotensin II-induced cardiac
inﬂammation through direct binding to Ang II24. We have also
reported that oxidized lipoproteins activate TLR4 through MD2
in atherosclerotic lesions25. Although the role of MD2 in
hyperglycemia-induced cardiac inﬂammatory injury is unknown,
these evidences point to the intriguing possibility that glucose or
glucose-derived factors interact with MD2 to activate TLR4.
The goal of this study is to systematically investigate the precise
mechanisms by which HG induces inﬂammatory activities in the
context of DCM. Our ﬁndings indicate that HG triggers rapid
generation of advanced glycation end products (AGEs), which
directly bind MD2 and lead to the activation of MD2-TLR4
signaling complex and inﬂammatory cardiac tissue injury. We
present a mechanism by which hyperglycemia triggers inﬂammatory injury in DCM, which underscores the importance of
MD2 as a new potential key therapeutic target for DCM.
Results
MD2-TLR4 is activated in cardiac tissues of diabetic mice. A
mouse model of type 1 diabetes was developed by administering
streptozotocin (STZ), as previously described by us8 and others26. Analysis of cardiac tissues showed a ﬁvefold increase in
MD2 protein levels at 16 weeks following the onset of diabetes
(Fig. 1a). TLR4 proteins were also increased at 16 weeks
(Fig. 1a). These changes were associated with increased
MD2-TLR4 complex formation as indicated by coimmunoprecipitation (Fig. 1b and Supplementary Fig. 1). To
identify the cellular source of MD2 in heart tissues, we performed immunostaining of tissue slices. Our results indicate colocalized MD2 immunoreactivity with cardiomyocyte α-actin
and macrophage F4/80 marker (Fig. 1c). In addition, some
MD2 staining labeled cells devoid of α-actin and F4/80. The
ﬁndings suggest that upregulated MD2 may primarily be
derived from cardiomyocytes and inﬁltrated macrophages.
2

MD2 deﬁciency reduces cardiac injury in diabetic mice. We
investigated the signiﬁcance of the elevated MD2-TLR4 expression in the cardiac tissue of diabetic mice by administering STZ in
Md2−/− (MD2KO) mice. Hyperglycemia was conﬁrmed for up to
16 weeks in wild-type (WT-STZ) and Md2−/− diabetic mice
(MD2KO-STZ) (Supplementary Fig. 2a). MD2KO did not show
any signiﬁcant changes in fasting blood glucose levels nor alter
body weights (Supplementary Fig. 2a, b).
We stained heart tissues from mice with H&E (Fig. 2a) to
measure cardiomyocyte cell size. Our results show increased
cardiomyocyte size in WT-STZ mice but not MD2KO-STZ mice
(Supplementary Fig. 2c). These results parallel serum creatine
kinase-muscle/brain (CK-MB) levels, which were signiﬁcantly
elevated in WT-STZ mice and dampened in MD2KO-STZ
(Table 1). WT-STZ mice also showed increased heart weight to
body weight ratios indicating cardiac hypertrophy, which was
reversed in MD2KO-STZ mice (Table 1). Moreover, MD2KOSTZ mice showed signiﬁcantly less severe reduced ejection
fraction and fraction shortening as evaluated by echocardiography (Table 1, Supplementary Fig. 3). Furthermore, E/A ratios and
isovolumic relaxation time (IVRT) were increased in WT-STZ
mice (Table 1), consistent with previous reports and indicative of
diastolic dysfunction. These cardiac abnormalities in WT-STZ
mice were associated with upregulation of genes (Fig. 2b) and
proteins (Fig. 2c, Supplementary Fig. 4) important for tissue
remodeling, such as atrial natriuretic peptide (ANP), collagen 1,
matrix metalloproteinase-2 (MMP2), MMP9, and transforming
growth factor β1 (TGFβ1). However, myocardial expression of
these genes and proteins in MD2KO-STZ mice were comparable
to MD2KO-Con (Fig. 2b, c, Supplementary Fig. 4). Furthermore,
staining of heart tissues with Sirius Red and Masson’s Trichrome
indicated excessive ﬁbrosis in WT-STZ mice but not MD2KOSTZ mice (Fig. 2d, e, Supplementary Fig. 5). These ﬁndings
indicate that MD2 deﬁciency protects against morphological and
functional cardiac abnormalities in diabetes.
We hypothesized that the protective effects of MD2 deﬁciency
were attributed to blockade of inﬂammatory responses downstream of MD2-TLR4. Indeed, myocardial tissue of WT-STZ
mice showed threefold increases in Tnfa and Il6 mRNA, however,
these cytokines remained at control levels in MD2KO-STZ mice
(Fig. 2f, g). NF-κB and MAPK, the major signaling targets of
MD2-TLR4, were also activated in the myocardial tissue of WTSTZ mice, as indicated by increased inhibitor of κB (IκB)
degradation and phosphorylated extracellular signal-regulated
kinase (ERK), c-jun N-terminal kinase (JNK), and p38 (Fig. 2h,
Supplementary Fig. 6). Analysis of heart tissues of MD2KO-STZ
mice showed a lack of these activations.
We next assessed whether MD2 deﬁciency prevents inﬁltration
of macrophages in the heart. We stained heart tissues for CD68
and show increased immunoreactivity in WT-STZ mice compared with WT-Con (Supplementary Fig. 7a). CD68 immunoreactivity was reduced in heart tissues of MD2KO-STZ mice,
suggesting decreased inﬁltration. Immunoblotting also showed
increased CD68 protein levels in heart lysates prepared from WTSTZ mice but not MD2KO-STZ mice (Supplementary Fig. 7b).
Furthermore, MD2KO-STZ mice showed no induction of
inﬂammatory cell adhesion molecules ICAM1 and VCAM1
(Supplementary Fig. 7b). These ﬁndings suggest that MD2
deﬁciency reduces adhesion molecules involved in macrophage
recruitment and prevents macrophage inﬁltration in diabetes.
Compound L6H21 is a selective MD2 inhibitor with antiinﬂammatory activities27. We investigated whether pharmacological MD2 inhibition by L6H21 also protects against the
development of myocardial injury in diabetic mice. As noted
for MD2KO mice, L6H21 treatment did not alter STZ-induced
decreased body weights or fasting blood glucose levels
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Fig. 1 MD2-TLR4 complex activation in hearts of diabetic mice. A mouse model of type 1 diabetes mellitus was developed by administering
streptozotocin to C57BL/6 mice. Heart tissues were harvested at 16 weeks [Con = non-diabetic controls, STZ = diabetic mice]. a Representative
immunoblot for MD2 and TLR4 in mouse cardiac tissue. GAPDH was used as loading control. Densitometric quantiﬁcation of blots showing MD2 (white
bars) and TLR4 (black bars) [n = 4; 3 Con and 3 STZ samples shown in immunoblots; means ± SEM]. b Representative immunoblots showing coimmunoprecipitation of TLR4 and MD2 in mouse heart tissues at 16 weeks following onset of diabetes [IP = precipitating antibody, IB = immunoblot
antibody; n = 4; 2 Con and 2 STZ samples shown in immunoblots]. c Representative immunoﬂuorescence staining of mouse heart tissues at 16 weeks for
MD2 (red), macrophage marker F4/80 (green), and myocyte marker α-actin (green). Slides were counterstained with DAPI (blue) [n = 4]. Source data
are provided as a Source Data ﬁle.

(Supplementary Fig. 8a, b). However, L6H21 treatment did
prevent STZ-induced ﬁbrosis (Supplementary Fig. 8c), as well as
tissue remodeling genes (Supplementary Fig. 8d, e). Moreover,
STZ-induced increases in myocardial TNF-α mRNA and protein
(Supplementary Fig. 8f–h), Il6 (Supplementary Fig. 8i), as well as
IκB degradation (Supplementary Fig. 8g) were signiﬁcantly
reduced by L6H21. These results show that L6H21 protects
against diabetes-induced inﬂammatory heart injuries, similar to
genetic MD2 deﬁciency.
MD2-TLR4 in cardiac cells induces inﬂammatory responses.
Our next objective was to determine whether a speciﬁc cell type in
the cardiac tissue is important for MD2-TLR4 signaling. Our
results indicated MD2 co-localization with α-actin and F4/80
markers (Fig. 1c). However, cells that were not marked by α-actin
and F4/80 also showed slight MD2 immunoreactivity. In addition
to cardiomyocytes and macrophages, cardiac tissue contains
abundant ﬁbroblasts and endothelial cells. Therefore, we harvested and compared the four cell types for MD2 expression. Our
results show high levels of MD2 mRNA and protein in primary
cardiomyocytes and macrophages (Supplementary Fig. 9).
Although endothelial cells and ﬁbroblasts express MD2, the levels
were signiﬁcantly lower compared with macrophages and
cardiomyocytes.
To build on these results, we reconstituted marrows of
irradiated MD2KO mice with marrow cells harvested from WT
mice or MD2KO mice. We then made these mice diabetic by STZ
and examined their heart tissues after 12 weeks. Compared with
sham WT mice, reconstitution of MD2KO mice with WT
marrow cells was associated with reduced ﬁbrosis (Supplementary
Fig. 10a) and lower mRNA levels of Anp, Col1a1, Mmp2, and
Tgfb1 (Supplementary Fig. 10b). These results show the
importance of cardiac MD2 in unregulated STZ-induced tissue
remodeling. Analysis of heart tissues from MD2KO mice

reconstituted with MD2KO marrow cells showed further
reductions in mRNA levels of Anp, Col1a1, and Mmp2, as
expected. Together with MD2 protein levels in harvested cardiac
cells, our results point to cardiomyocyte and macrophage as
primary cellular targets of MD2-TLR4 signaling in diabetes.

Glucose activates MD2-TLR4 in cardiomyocytes and macrophages. We next examined how HG promoted inﬂammatory
responses through MD2-TLR4 signaling. As mentioned above,
numerous studies have indicated increased levels of TLR4 pathway proteins in diabetes and cells exposed to HG11–15. Inhibition
of TLR4 also reduces inﬂammatory cytokine expression, implicating activated TLR4 signaling upon HG exposure of cells13,28.
To understand how HG activates TLR4, we ﬁrst excluded osmotic
stress contributing to inﬂammatory signaling. Rat heart-derived
H9C2 cells and mouse primary peritoneal macrophages (MPMs)
showed HG-induced TNF-α and IL-6 production (Supplementary
Fig. 11a–e). These inductions were not seen with mannitol
indicating the involvement of inﬂammatory signaling and not
osmotic stress. We next determined the effects of HG in MD2TLR4 complex formation in H9C2 cells. We exposed H9C2 cells
to HG (33 mM glucose) for up to 30 min and analyzed MD2TLR4 complex formation by co-immunoprecipitation. We found
that HG induced MD2-TLR4 complex by 5 min, and this interaction was sustained for 30 min (Fig. 3a). Using glucose concentration ranging from 7 to 60 mM, we show signiﬁcant MD2TLR4 complex formation occurring at levels ≥30 mM (Fig. 3b).
Moreover, H9C2 cells co-transfected with Flag-TLR4 and HATLR4 plasmids indicated that HG signiﬁcantly induces TLR4
dimerization at 15 min (Supplementary Fig. 12). These ﬁndings
support the thesis that HG induces rapid MD2-TLR4 complex
formation and TLR4 dimerization. Pretreatment of H9C2 cells
with the MD2 inhibitor L6H21 prior to HG exposure signiﬁcantly
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Fig. 2 MD2 deﬁciency prevents diabetes-induced cardiac injury. Diabetes was induced in C57BL/6 wild-type and MD2−/− mice by streptozotocin. Heart
tissues were harvested at 16 weeks [WT-Con = non-diabetic wild-type controls, WT-STZ = diabetic wild type, MD2KO-Con = non-diabetic MD2−/−,
MD2KO-STZ = diabetic MD2−/−]. a Representative H&E staining of cardiac tissues [n = 6]. b mRNA levels of cardiac tissue Anp, Col1a1, Mmp9, Mmp2,
and Tgfb1 normalized to Actb [means ± SEM; n = 6 per group; *p < 0.05, **p < 0.01, ***p < 0.001 compared with WT-Con; #p < 0.05, ##p < 0.01 compared
with WT-STZ; P-values by unpaired t test are indicated]. c Representative immunoblots showing cardiac tissue ANP, Col 1, MMP-9, MMP-2, and TGF-β.
GAPDH was used as a loading control [n = 6; 3 samples per group shown]. d, e Representative staining images of mouse heart sections showing Sirius Red
(d) and Masson’s Trichrome (e) (n = 6 per group). f, g qPCR analysis of Tnfa and Il6 mRNA levels in cardiac tissues [means ± SEM; n = 6 per group].
h Representative immunoblots showing levels of IκB and phosphorylated ERK, JNK, and P38 in mouse cardiac tissues. GAPDH was used as loading control
[n = 6; 3 samples per group shown]. Source data are provided as a Source Data ﬁle. P-values by one-way ANOVA in b, f, and g followed by Tukey’s post
hoc test are indicated.
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Table 1 Biometric and echocardiographic parameters of DM1 mice.
Parameter
IVSd (mm)
IVSs (mm)
LVd (cm)
LVs (cm)
FWd (mm)
FWs (mm)
PWd (mm)
PWs (mm)
EF%
FS%
E (m/s)
A (m/s)
E/A
IVRT(ms)
HW (mg)
BW (g)
HW/BW (mg/g)
CK-MB

WT-Con (n = 6)a
0.84 ± 0.03
1.10 ± 0.08
0.26 ± 0.01
0.14 ± 0.003
0.88 ± 0.037
1.123 ± 0.07
0.84 ± 0.03
1.06 ± 0.04
82.12 ± 2.0
44.48 ± 1.9
0.452 ± 0.07
0.531 ± 0.02
0.842 ± 0.13
12.1 ± 1.38
125.1 ± 3.28
29.68 ± 0.95
4.218 ± 0.065
22.15 ± 4.174

WT-STZ (n = 7)a
0.74 ± 0.02*
0.95 ± 0.02*
0.24 ± 0.02
0.13 ± 0.002
0.73 ± 0.009***
0.96 ± 0.02**
0.75 ± 0.02*
0.95 ± 0.02
70.57 ± 2.3**
36.14 ± 2.0**
0.458 ± 0.06
0.322 ± 0.06
1.615 ± 0.20**
21.14 ± 1.86*
117.8 ± 1.42
25.30 ± 0.38
4.660 ± 0.031**
59.47 ± 4.200***

MD2KO-Con (n = 6)a

MD2KO-STZ (n = 7)a

0.77 ± 0.01
0.96 ± 0.02
0.25 ± 0.01
0.14 ± 0.007
0.77 ± 0.009
0.99 ± 0.01
0.76 ± 0.02
0.98 ± 0.02
80.78 ± 1.7
43.50 ± 1.7
0.612 ± 0.04
0.632 ± 0.06
1.002 ± 0.09
13.8 ± 2.12
131.0 ± 4.55
32.17 ± 1.70
4.093 ± 0.082
28.88 ± 1.835

0.77 ± 0.01#
0.96 ± 0.01#
0.25 ± 0.01
0.14 ± 0.005
0.76 ± 0.012#
0.98 ± 0.02#
0.78 ± 0.01#
0.98 ± 0.02
80.37 ± 1.3##
42.84 ± 1.2##
0.583 ± 0.05
0.628 ± 0.08
1.033 ± 0.15#
16.3 ± 2.22#
116.0 ± 2.92
27.07 ± 0.48
4.281 ± 0.075#
37.25 ± 2.820##

IVSd interventricular septal dimension in diastole, IVSs interventricular septal dimension in systole, LVd left ventricle in diastole, LVs left ventricle in systole, FWd left ventricular free wall in diastole, FWs
left ventricular free wall in systole, PWd posterior wall thickness in diastole, PWs posterior wall dimension in systole, EF ejection fraction, FS fractional shortening, E peak mitral E velocity, A peak mitral A
velocity, IVRT isovolumic relaxation time, HW heart weight, BW body weight, CK-MB creatine kinase-muscle/brain.
aValues shown as mean ± SEM.
*p < 0.05, **p < 0.01, ***p < 0.001 compared with WT-Con; #p < 0.05, ##p < 0.01 compared with WT-STZ. P-values by one-way ANOVA followed by Tukey’s post hoc test are indicated.

blocked MD2-TLR4 complex formation (Fig. 3c), suggesting that
MD2 was essential in mediating HG-induced TLR4 activation.
Activation of the MD2-TLR4 complex leads to recruitment of
MyD88, resulting in activation of MAPK and NF-κB. We silenced
MD2 using targeted siRNAs in H9C2 cells (Fig. 3d). In negative
control-transfected H9C2 cells, HG increased immunoprecipitation pull-down of MyD88 with TLR4, but not in cells with MD2
knockdown (Fig. 3e). Moreover, MD2 knockdown in H9C2 cells
reduced HG-induced degradation of IκB (Fig. 3f), indicative of
NF-κB inhibition, and inhibited HG-induced phosphorylation of
MAPK (ERK, JNK, and P38) (Fig. 3g). These ﬁndings were
corroborated in cells treated with MD2 inhibitor L6H21 and
MD2 neutralizing antibody (Supplementary Fig. 13a). Not
surprisingly, both MD2 knockdown (Fig. 3h, i) and L6H21
(Supplementary Fig. 13b, c) signiﬁcantly inhibited HG-induced
mRNA of Tnfa and Il6.
To build on these results, we evaluated the consequence
of TLR4 deﬁciency in HG-induced inﬂammatory signaling.
siRNA-mediated knockdown of TLR4 reduced Tlr4 levels to
~50% of control cells (Supplementary Fig. 14a) and effectively
prevented HG-induced increases in Tnfa and Il6 (Supplementary
Fig. 14b, c).
We conﬁrmed these ﬁndings from H9C2 in primary
cardiomyocytes from Sprague-Dawley rats. Our results indicate
that L6H21 pretreatment at 10 μM inhibits HG-induced MD2TLR4 complex formation, IκB degradation, MAPK activation,
and Tnfa levels in rat primary cardiomyocytes (Supplementary
Fig. 15). We then examined macrophages and show that L6H21
prevents HG-induced formation of MD2-TLR4 complex and
TLR4-MyD88 complex in MPMs (Fig. 3j). L6H21 pretreatment
also inhibited HG-induced TNF-α and IL-6 production by MPMs
(Fig. 3k, l). Induction of TNF-α and IL-6 by HG was not seen in
MPMs harvested from MD2KO mice, conﬁrming that HG
activates MD2-dependent pro-inﬂammatory signaling.
Our in vivo data indicated that MD2 deﬁciency prevents
cardiac ﬁbrosis. Therefore, we evaluated indices of tissue
remodeling in primary cardiomyocytes exposed to HG. We show
that HG exposure for 12–24 h increases Tgfb1 and Mmp2,
however, siRNA-mediated MD2 knockdown prevented these
HG-induced increases (Supplementary Fig. 16a). Moreover,

L6H21 pretreatment of rat primary cardiomyocytes inhibited
HG-induced increases in protein levels of TGFβ, MMP-2,
Collagen 1, and myosin heavy chain (MyHC) (Supplementary
Fig. 16b, c). These in vitro ﬁndings corroborate our data obtained
from STZ-induced model of type 1 diabetes, supporting a MD2dependent mechanism.
HG likely activates MD2-TLR4 indirectly. Our next goal was to
explore the mechanisms by which HG activates MD2. Our
in vitro ﬁndings indicated that HG rapidly stimulates the formation of MD2-TLR4 complex in H9C2 cells and MPMs
(Fig. 3a). MD2 is an extracellular protein, and functions as a coreceptor of TLR4 at the cell surface. As shown in Fig. 4a, there are
two potential extracellular pathways by which HG may activate
MD2-TLR4 complex: (1) HG directly interacts with MD2 protein
or (2) HG works in concert with extracellular factors (e.g., in
blood and interstitium) to interact with MD2.
We ﬁrst examined if the glucose uptake and intracellular
glucose is required for rapid MD2-TLR4 activation. Cardiac
myocytes express glucose transporter-4 (GLUT4) to transport
glucose into cells29. We found that increasing extracellular
glucose levels by GLUT4 knockdown in H9C2 cells (Fig. 4b)
results in enhanced HG-induced MD2-TLR4 complex formation
(Fig. 4c). Excessive glucose in cells increased intracellular reactive
oxygen species (ROS), which has been reported to induce TLR412.
We tested the idea that HG-induced ROS may modulate TLR4 in
macrophages and H9C2 cells. Our results showed that ROS
scavenger N-acetylcysteine (NAC) did not reduce the MD2-TLR4
interaction in cells stimulated with HG for 15 min (Supplementary Fig. 17a, b). As reported previously12, pretreatment of cells
with NAC reduced the levels of Tnfa, Il6, and Tlr4 induced by a
12-h HG challenge (Supplementary Fig. 17c, e). These results
show that intracellular HG increases the expression of Tlr4 via
ROS but is not involved in MD2-TLR4 complex formation and
TLR4 activation.
We then explored the two potential mechanisms by which
extracellular glucose may activate MD2-TLR4 complex at the cell
surface. We tested whether glucose directly binds to the MD2
protein, like LPS. The direct glucose-MD2 interactions were
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Fig. 3 High glucose activates MD2-TLR4 signaling in cardiac cells. a, b Representative immunoblots showing co-immunoprecipitation of MD2 and TLR4
in H9C2 cells exposed to HG for varying time points (a) and concentration (b) [n = 3]. c H9C2 cells were pretreated with 10 μM MD2 inhibitor L6H21 for
30 min before exposure to HG (33 mM glucose) for 5 min. Representative immunoblots showing co-immunoprecipitation of MD2 and TLR4 [n = 3].
d Western blot analysis showing levels of MD2 protein following transfection of H9C2 cells with MD2 siRNA [si-MD2 = MD2 targeting siRNA, NC =
negative control; n = 3]. e Co-immunoprecipitation of TLR4 and MyD88 in H9C2 cells transfected with MD2 siRNA (si-MD2) and exposed to HG (33 mM
glucose, 15 min) [n = 3]. f, g Representative blots of IκB and phosphorylation of ERK, JNK, and P38 in H9C2 cells transfected with MD2 siRNA and exposed
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examinations]. k, l Levels of TNF-α and IL-6 in culture media of MPMs isolated from non-diabetic WT and MD2KO mice. Cells were pretreated with 10 μM
L6H21 for 1 h and then exposed to HG (33 mM glucose) for 24 h. TNF-α and IL-6 levels were determined by ELISA [means ± SEM; n = 3 examinations].
Source data are provided as a Source Data ﬁle. P-values by one-way ANOVA in h, i, k, and l followed by Tukey’s post hoc test are indicated.

determined using recombinant human MD2 (rhMD2) in an
isothermal titration calorimetry (ITC) assay. Surprisingly, the
analysis was negative, indicating no direct glucose-rhMD2
interaction (Fig. 4d). Therefore, we evaluated the importance of
serum in HG-induced inﬂammatory responses (alternate extracellular mechanism). Results indicated that HG-induced (33 mM
glucose, 24 h) TNF-α and IL-6 in MPMs was suppressed in the
absence of serum (Fig. 4e). These results contrast with LPS
(0.5 μg/mL, 24 h) which induces TNF-α and IL-6 in the presence
or absence of serum (Fig. 4f). Similar responses were observed in
H9C2 cells using qPCR analysis of cytokine mRNA (Supplementary Fig. 18). Interestingly, addition of 5 or 10% fetal bovine
serum (FBS) to MPMs which were originally cultured without
serum, restores HG-responsiveness and induces TNF-α and IL-6
(Fig. 4g, h). HG also failed to induce the formation of MD2-TLR4
and TLR4-MyD88 complexes in the absence of serum, whereas
addition of serum rescues complex formation and recruitment of
MyD88 (Fig. 4i). Similar responses to serum occurred in H9C2
cells, in which HG was unable to induce cytokine production,
MD2-TLR4 complex formation, or recruit MyD88 (Fig. 4j–l).
6

The requirement of serum in HG-responsiveness of MPMs and
H9C2 cells raises several important questions. Although we
cultured and performed our studies in heat-inactivated serum,
complement activation may potentially be involved HG-induced
TNF-α and IL-6 production. To test this, H9C2 cells were
cultured in media containing 10% heat-inactivated FBS or serum
that did not undergo heat-inactivation, for 10 days. Cells were
then exposed to HG (33 mM glucose) in the respective serum
groups for 24 h and mRNA levels of Tnfa and Il6 were
determined. We show no signiﬁcant difference in HG-induced
Tnfa and Il6 (Supplementary Fig. 19). We also tested whether
altered glycolysis was responsible for MD2-TLR4 interaction in
cells exposed to HG. We assessed glycolytic function through
extracellular acidiﬁcation rate (ECAR) in H9C2 and MPMs
exposed to HG. Our results indicate increased glycolysis in MPMs
but not H9C2 cells exposed to 33 mM glucose (Supplementary
Fig. 20). To rule out glycolysis in inducing MD2-TLR4 activation,
we pretreated H9C2 cells with glycolysis inhibitor 2-deoxyglucose (2-DG) and then exposed the cells to HG. Coimmunoprecipitation showed that 2-DG does not alter HG-

NATURE COMMUNICATIONS | (2020)11:2148 | https://doi.org/10.1038/s41467-020-15978-3 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15978-3

a

d
0

(2)

(1) Direct, extracellular
MD-2

Intracellular glucose

NC

53 kD

GAPDH

37 kD

c

HG
NC

NC

si-GLUT4

IB: TLR4

90 kD

IP: MD2

20 kD
H9c2 cells

g

p = 0.0094 p = 0.0086

p = 0.012 p = 0.021

100

50

0
TNF-α

j

l

Tnf- mRNA in H9c2

40

p < 0.0001
p < 0.0001

6
4
2
0
trl

C

HG

l

Ctr

HG S 5%
10%
B
BS
+F
+F
HG

HG

2.5

3.0

3.5

LPS serum

150

LPS no serum
p = 0.0009 p = 0.84

p = 0.0023 p = 0.67

100

50

0
IL-6

i
HG no serum
Ctrl

p < 0.0001
p < 0.0001

0

5

10 (FBS%)

IB: TLR4

90 kD

IP: MD2

20 kD

IB: MyD88

33 kD

IP: TLR4

90 kD

30
20
10
0
l

Ctr

k

HG

l

Ctr

MPM cells

5%
HG
10%
BS FBS
+F
+
G
HG
H

Il-6 mRNA in H9c2
No serum
p = 0.009
p < 0.0001
p < 0.0001

10
Relative amount of mRNA

Relative amount of mRNA

p = 0.0057

1.5
2.0
Mole ratio

TNF-α

p = 0.0007

No serum
8

1.0

No serum

5%
0%
HG
S1
BS
FB
+F
G+
HG

Ctr

0.5

IL-6 in MPM

Relative amount of cytokines
(compared to ctrl)

Relative amount of cytokines
(compared to ctrl)

p < 0.0001
p < 0.0001

0
HG

Enthalpy (kJ/mol)

IL-6

h

50

l

Corrected heat
rate (μJ/s)

Ctrl

HG serum
HG no serum

150

100

Ctr

7000

f

No serum
150

6000

2.0

Ctrl

TNF-α in MPM
p < 0.0001

5000

1.0

e

si-GLUT4

GLUT4

Relative amount of cytokines
(compared to HG serum)

b

Time (s)
3000 4000

3.0

0
–1000
–2000
–3000
–4000
–5000
–6000
–7000
–8000
0.0

Enthalpy (kJ/mol)

GLUT4

TLR4

(1)

2000

4.0

Relative amount of cytokines
(compared to LPS serum)

Glucose

Corrected heat
rate (μJ/s)

(2) Indirectly, extracellular

1000

l

HG no serum
Ctrl

0

5

10 (FBS%)

IB: TLR4

90 kD

6

IP: MD2

20 kD

4

IB: MyD88

33 kD

8

2
90 kD

IP: TLR4
0
C

trl

HG

C

trl

HG S 5%
0%
B
S1
+F
FB
G+

H9c2 cells

HG
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NATURE COMMUNICATIONS | (2020)11:2148 | https://doi.org/10.1038/s41467-020-15978-3 | www.nature.com/naturecommunications

7

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15978-3

c

a

e

WT-Ctrl
WT + AGE
MD2KO-Ctrl
MD2 KO + AGE

AGE in MPM medium

0

1200
1000
800

No serum

600

p > 0.05

5

15

30 min

IB: TLR4

90 kD

IP: MD2

20 kD

MPM cells

400
200
0

HG

d

30
0

TNF-α

IL-6

Ctrl
AGE
Si-MD2
Si-MD2 + AGE

0

400

IB: TLR4

200

IP: MD2

5

15

30 min
90 kD
20 kD

H9c2 cells
0

Relative amount of mRNA

AGE

p > 0.05

HG

p < 0.0001 p < 0.0001

60

f

No serum

600

p < 0.0001 p < 0.0001

90

AGE in H9c2 medium
p < 0.05

C
5 trl
m
15 in
m
in
1
h
6
h
12
h
C
5 trl
m
15 in
m
in
1
h
6
h
12
h

Concentration of AGE (pg/ml)

120

MPM cells

HG

b
800

Relative amount of cytokines
(compared to AGEs %)

AGE

C
5 trl
m
15 in
m
in
1
h
6
h
12
h
C
5 trl
m
15 in
m
in
1
h
6
h
12
h

Concentration of AGE (pg/ml)

p < 0.05

1400

5

p < 0.0001 p < 0.0001

H9c2 cells

p < 0.0001 p < 0.0001

4
3
2
1
0

Tnf-

Il-6

HG
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induced MD2-TLR4 interaction in H9C2 cells (Supplementary
Fig. 21a). Similarly, 2-DG dose not suppress HG-induced Tnfa
and Il6 in H9C2 cells (Supplementary Fig. 21b, c). Taken
together, our results show that HG activates MD2-TLR4 signaling
and this response is dependent on the presence of serum.
HG produces AGE products that activate MD2. AGE product
generation is a well-established event for various proteins exposed
to HG, and the pathogenesis of diabetes and cardiovascular diseases. We speculated that HG may produce AGE products in
serum-containing medium to initiate MD2-dependent inﬂammatory responses. We exposed MPMs and H9C2 cells to HG in
the presence or absence of serum for increasing duration and
assessed AGE formation. Our results show that MPMs exposed to
HG in the absence of serum were unable to generate AGEs;
whereas in the presence of serum, HG increased AGE products by
approximately threefold within 5 min (Fig. 5a). Similarly, HG
increased AGE products in H9C2 cell media when exposed in the
presence of serum (Fig. 5b).
Since AGE products are heterogenous, formed from different
intermediates, and have differential activities in cells30, we
measured methylglyoxal (MGO) and Nε-carboxymethyl-lysine
(CML) in media of H9C2 exposed to HG. Our results show that
HG exposure of H9C2 cells for up to 15 min does not increase
8

CML levels and no changes were seen in MGO levels for up to 60
min HG exposure (Supplementary Fig. 22a–c). To conﬁrm these
extracellular reactions, we incubated cell-free complete growth
media containing serum with 33 mM glucose for 15 min and
measured the levels of AGE-, MGO-, and CML-modiﬁed
proteins. Our results show that glucose exposure of serumcontaining media rapidly generates AGE-modiﬁed serum proteins, while we did not observe increases in MGO or CML
(Supplementary Fig. 22d).
At least in our system, at appears that AGE-modiﬁed proteins
may be involved in HG inﬂammatory responses. Direct exposure
of MPMs and H9C2 cells (Fig. 5c, d) to 30 μg/mL AGE-modiﬁed
bovine serum albumin (glucose-derived, glycolaldehyde-mediated
AGE-BSA) for 15 min caused rapid association between MD2 and
TLR4. Compared with AGE-BSA, however, neither MGO-BSA,
nor CML-BSA at 30 μg/mL induced MD2-TLR4-MyD88 interaction in MPMs and H9C2 cells (Supplementary Fig. 23a–c).
Subsequently, incubation with AGE-BSA, but not MGO-BSA
and CML-BSA for 1 h induced I-κB degradation in MPMs and
H9C2 cells (Supplementary Fig. 23c). AGE-BSA also induced TNFα and IL-6 in MPMs harvested from WT mice (Fig. 5e) consistent
with activated MD2-TLR4. The level of TNF-α and IL-6 in MPMs
isolated from MD2KO mice was signiﬁcantly less compared with
cells from WT mice, conﬁrming MD2 involvement. Similarly, direct
exposure of H9C2 cells to AGE-BSA induced a threefold increase in
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Tnfa and Il6 (Fig. 5f), which was blocked in cells transfected with
MD2 siRNA. As expected, MGO-BSA and CML-BSA at 30 μg/mL
failed to induce Tnfa and Il6 in MPMs (Supplementary Fig. 23d).
These results indicate that HG-derived AGE products activate MD2
and induce inﬂammation.
AGEs directly bind MD2 and activate MD2-TLR4. The above
data suggest that HG-generated AGE products directly bind to
and activate MD2-TLR4 signaling complex. We investigated this
idea using a combination of approaches. We ﬁrst exposed H9C2
cells to HG for 5-15 min and show rapid pull-down of AGE using
either MD2 or TLR4 as the precipitating antibody (Fig. 6a). H9C2
cells challenged directly with puriﬁed AGE-BSA also showed the
formation of AGE-MD2-TLR4 complex in a rapid fashion
(Fig. 6b). Interestingly, MD2 knockdown reduced the level of
AGEs associating with TLR4 (Fig. 6c), implicating MD2 as a
required binding partner for AGEs. In support of this ﬁnding,
TLR4 knockdown showed no effect on the HG-induced AGEMD2 interaction (Fig. 6d). Pretreatment of cells with MD2
inhibitor L6H21 also prevented pull-down of AGEs following
MD2 or TLR4 antibody precipitation in HG-challenged H9C2
cells (Fig. 6e). Although this co-IP data supports direct interactions of AGE products with MD2, it cannot rule out participation
by other molecules.
We then investigated AGE-MD2 interactions under cell-free
conditions using ITC and ELISA. ITC measurements of rhMD2
reacting with AGE-BSA indicated direct interaction, producing a
Kd value of 81 µM (Fig. 6f). A sandwich ELISA based on AGEand MD2-antibodies was used to conﬁrm ITC data. Results
indicated that addition of puriﬁed AGE-BSA and rhMD2 (1:1 or
1:0.5) in PBS correlated with detection of AGE-MD2 complex
(Fig. 6g). Thus, the data obtained cell-based and cell-free studies
provide strong evidence that AGEs directly bind MD2, which
would form a heterotrimer of AGE-MD2-TLR4 on the cell
surface, leading to subsequent activation of the pro-inﬂammatory
signaling cascades.
Although the AGE-BSA preparation used in our study
contained very low endotoxin levels, we explored the possibility
that MD2-TLR4 activation in response to AGE-BSA may have
resulted from endotoxin contamination. To test this, we exposed
H9C2 cells to AGE-BSA with or without polymyxin B. Polymyxin
B binds to lipid A of LPS and will mitigate any false-positive
results from endotoxin contamination. Our results show that
presence of polymyxin B does not alter AGE-BSA-induced MD2TLR4 complex formation or induction of Tnfa and Il6 in H9C2
cells (Supplementary Fig. 24).
We also tested the possibility that the prototypical receptor for
AGE (RAGE) may contribute to HG- and AGE-induced
inﬂammatory responses in cardiac cells. We knocked down the
expression of RAGE in H9C2 cells using shRNA and achieved
90% silencing (Supplementary Fig. 25a). We found that silencing
RAGE does not affect HG-induced MD2-TLR4 complex formation (Supplementary Fig. 25b). However, RAGE silencing reduced
the level of cytokine induction by HG, suggesting that RAGE
activation may also contribute to the inﬂammatory responses
(Supplementary Fig. 25c, d). Similarly, challenging cells with
AGE-BSA did not alter AGE-MD2-TLR4 interaction upon RAGE
knockdown (Supplementary Fig. 25e) but prevented the full
induction of cytokines (Supplementary Fig. 25f, g). These results
indicate that under our experimental conditions, HG and AGE
products activate distinct MD2-TLR4 and RAGE proinﬂammatory signaling pathways.
Elevated AGE products and MD2-AGE complexes in diabetes.
Our ﬁndings from cellular and molecular studies suggested that

ARTICLE

one mechanism by which HG causes cardiac cell injury is by
direct AGE interaction with MD2 to activate MD2-TLR4 signaling complex. To explore this complex formation in animal
models of diabetes and in human subjects, we ﬁrst determined the
levels of AGE products. Measurement of AGE content in myocardial tissues of STZ-induced type 1 diabetic mice showed a
twofold increase over levels in non-diabetic controls (Fig. 7a).
Serum levels of AGE products were also increased in WT-STZ
mice (Supplementary Fig. 26a). No changes in AGE content was
observed in MD2KO-STZ mice compared with WT-STZ mice.
Consistent with our cell culture studies, no increases in MGO and
CML levels were noted in control and diabetic mice (Supplementary Fig. 26b-c). MD2 antibody pulled down increased
amounts of AGE and TLR4 in lysates prepared from WT-STZ
mice (Fig. 7b), suggesting increased MD2-AGE and MD2-TLR4
complex formation. Since MD2 also exists in a soluble form
(sMD2) and appears to be important for sensing endogenous
ligands31,32, we speculated that circulating sMD2 and AGEs may
form complexes in the context of diabetes. We detected serum
sMD2-AGEs complexes using a sandwich ELISA and show
approximately twofold higher content of MD2-AGE complexes in
WT-STZ mice compared with WT-Con (Fig. 7c). Parallel analyses were made in a type 2 diabetic mouse model (db/db).
Analysis of cardiac tissues in db/db mice showed increased AGE
levels (Fig. 7d), enhanced MD2-AGE and MD2-TLR4 complexes
(Fig. 7e), and MD2-AGE complexes in serum (Fig. 7f), compared
with non-diabetic db/m controls. Furthermore, as with the STZinduced model of type 1 diabetes, myocardial tissue of db/db mice
showed increased levels of TNF-α, IL-6, and MD2 levels compared with db/m controls (Supplementary Fig. 27a–c).
We wanted to explore whether enhanced MD2-AGE interaction is evident in human subjects with diabetes. Blood was
collected from healthy subjects, and diabetic subjects with or
without evidence of DCM. We isolated peripheral blood mononuclear cells (PBMCs) and prepared serum. Analysis of serum
content of AGE products showed 2-fold greater levels in DCM
subjects compared with healthy subjects (Fig. 7g). Interestingly,
we observed that HG addition to healthy human serum
signiﬁcantly induces AGE production within 5 min (Supplementary Fig. 28a), which is consistent with our ﬁnding that HG
rapidly produces AGE in culture media containing serum
(Fig. 5a–d). In addition to increased serum AGE levels, PBMCs
isolated from diabetic subjects with DCM or without cardiomyopathy showed elevated levels of MD2 proteins (Supplementary
Fig. 28b), and increased AGE-MD2-TLR4 complexes (Fig. 7h).
Analysis of serum samples further showed elevated soluble MD2
(Supplementary Fig. 28c), inﬂammatory cytokines TNF-α and IL6 (Supplementary Fig. 28d–e), and MD2-AGE complexes (Fig. 7i)
in diabetic subjects with DCM and without cardiomyopathy,
compared with healthy samples. Our identiﬁcation of increased
MD2-AGE complexes in diabetic mice and human subjects
extended the ﬁndings obtained from in vitro studies, and
strengthen the idea that direct AGE-MD2 interactions are the
initiating events driving the cardiac inﬂammatory state in
diabetes.
Discussion
Diabetic patients commonly succumb to cardiovascular complications. Yet, the mechanisms by which high circulating glucose
levels cause diabetic inﬂammatory tissue injury remain poorly
understood. Experimental evidence shows an overactive
TLR4 signaling pathway, linking MyD88 with the activation of
MAPK and NF-κB and upregulation of proinﬂammation factors,
as a critical factor in diabetic myocardial injury and
dysfunction9,19–22,33. Our study focused on understanding how
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Fig. 6 AGE products bind to MD2. a Representative immunoblot showing co-immunoprecipitation of AGE-MD2 and AGE-TLR4 complexes in H9C2 cells
exposed to HG (33 mM glucose) for indicated times [n = 3]. b Representative blots of co-immunoprecipitated AGE-MD2 and AGE-TLR4 complexes in
H9C2 cells challenged with 33 μg/mL AGE-BSA for indicated times [n = 3]. c Representative blots of co-immunoprecipitated AGE-TLR4 complexes in
H9C2 cells transfected with MD2 siRNA (siMD2) and exposed to HG (33 mM glucose) for 5 min [n = 3]. d Representative blots of co-immunoprecipitated
AGE-TLR4 complexes in H9C2 cells transfected with TLR4 siRNA (siTLR4) and exposed to HG (33 mM glucose) for 5 min [n = 3]. e Coimmunoprecipitation of AGE-MD2 and AGE-TLR4 complexes in H9C2 cells pretreated with 10 μM L6H21 for 30 min and then challenged with HG (33 mM
glucose) for 5 min [n = 3]. f Isothermal titration calorimetry analysis of interactions between AGE-BSA and rhMD2. Representative image was shown from
three independent experiments. g Sandwich ELISA analysis of AGE-MD2 interaction. AGE-BSA and rhMD2 proteins were added at ratios of 1:1 or 1:0.5, or
each alone to bovine AGE ELISA plates. Complexes were detected by anti-human MD2 antibody and TMB chromagen [means ± SEM; n = 3 examinations].
Source data are provided as a Source Data ﬁle. P-values by one-way ANOVA in g followed by Tukey’s post hoc test are indicated.

glucose activates the TLR4 signaling cascade and induces
inﬂammatory responses. Our ﬁndings support a working model
in which high levels of glucose induce an AGE-dependent activation of the MD2-TLR4 immune signaling complex in macrophages and cardiomyocytes, resulting in inﬂammatory factor
expression and myocardial injury (Fig. 8).
10

Increased levels of TLR4 and downstream accessory proteins
have been reported to be increased in human diabetes and in
experimental models. Speciﬁcally, studies have shown the HG
induces TLR4 in myocytes11 and monocytes12. Diabetic mice and
rats have also been reported to express upregulated TLR4 in heart
tissues17,18. Studies have also shown that oxidative stress may
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increase TLR4 proteins12. What has remained elusive, however, is
how TLR4 is activated by glucose or other factors in diabetes. Our
studies have demonstrated a rapid mechanism of direct activation
of TLR4 by HG. Importantly, our studies have identiﬁed MD2 as
a requisite for TLR4 activation. In diabetic MD2 knockout mice
or diabetic mice administered L6H21, NF-κB, and MAPK pathways were inhibited, and production of pro-inﬂammatory
molecules was suppressed, indicating that MD2 deﬁciency

correlated with suppressed inﬂammation. Moreover, diabetesinduced myocardial ﬁbrosis, cardiomyocyte hypertrophy, and
cardiac dysfunctional was effectively prevented with MD2 deﬁcit.
These results strongly suggest that MD2 plays a critical role in
initiating diabetes-associated inﬂammatory injury leading to
functional and structural deﬁcits in the heart.
Our studies show that TLR4 is activated when HG-derived
AGE products directly engage the TLR4 pathway (Fig. 8). AGE
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Fig. 8 Working model of AGE-induced MD2-TLR4 activation in diabetes. Schematic illustration showing the key ﬁndings of the study. High levels of
glucose generate AGE products in the extracellular environment. AGE products bind directly to MD2 and lead to activation of the immune signaling
complex MD2-TLR4. Intracellular adaptor proteins such as myeloid differentiation primary response protein-88 (MyD88) are recruited to AGE-MD2-TLR4
complex. TLR4 then leads to activation of mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways, and regulation of genes involved in
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products are generated by non-enzymatic glycation/oxidation of
proteins, lipids or nucleotides which accumulate in the extracellular matrix, both in tissues as well as in the circulation34. AGE
products are known to signal predominantly through the prototypical RAGE, but can also serve as ligands for other receptors
including macrophage scavenger receptor type II and CD3635.
Our studies support an alternate signaling pathway to RAGE, in
which AGE products bind and activate the MD2-TLR4 immune
signaling complex. In addition, cell-free studies using puriﬁed
MD2 and AGE-BSA corroborated direct AGE binding to MD2.
Moreover, both MD2-TLR4 and RAGE appeared to contribute to
HG- and AGE-induced pro-inﬂammatory factor induction. It is
unknown whether RAGE and MD2-TLR4 are completely distinct
pathways or play an interacting role. Recent studies utilizing high
mobility group box 1 (HMGB1) which is a ligand for both
TLR436 and RAGE37, offers some insight. HMGB1 and AGE
products can activate MyD88 through RAGE38. As MyD88
appears to be shared between TLR4 and RAGE, it is possible that
MD2-TLR4 and RAGE crosstalk to fully engage MyD88 in cardiomyocytes. However, since we are able to completely normalize
inﬂammatory cytokine production in response to HG and AGE
by blocking MD2 (L6H21, MD2 siRNA, or in MD2KO cells), we
believe that MD2-TLR4 pathway plays a pivotal role in inﬂammatory responses to HG and AGE. This would suggest that even
RAGE activity would require TLR4 activation. Indeed, this notion
is supported by recent studies by Valencia and colleagues
who reported that AGE products fail to bind RAGE and upregulate VCAM-1 or TNF-α in endothelial and mononuclear cells
unless TLR4 was activated39. Future studies utilizing cardiomyocytes and macrophages with RAGE knockout and selective
engagement of TLR4 versus RAGE would be needed to conﬁrm
these ideas.
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Another important ﬁnding in our study was increased levels of
AGE-MD2 complexes in diabetic human and mouse serum.
Diabetic conditions are causally linked to elevated circulating
AGEs40, and this was further corroborated by our study in which
elevated AGE products were detected in serum of human subjects
with DCM, and mouse models of type 1 and 2 diabetes. Moreover, MD2 is a secreted protein and its soluble form, sMD2, is
found in the circulation32,41. Elevated circulating sMD2 levels are
associated with patients with severe infections, such as sepsis and
rheumatoid arthritis41. Although the exact function of sMD2 is
not fully deﬁned, studies have shown that complex formation
between sMD2 and LPS increases circulating MD2 protein halflife42 and that this complex interacts with TLR4-expressing cells
to confer LPS sensitivity32. Interestingly, even without interacting
with LPS, sMD2 is able to bind cell-surface TLR443. Therefore,
the consensus is that sMD2 facilitates innate immune responses,
in part through activating TLR4 in MD2-deﬁcient cells. Although
sMD2 level was only measured in human serum samples in our
study, we did detect signiﬁcantly elevated AGE-MD2 complexes
in serum of diabetic subjects, and in both models of diabetic mice.
In addition, myocardial tissues from diabetic mice and PBMCs
from human subjects showed elevated AGE-MD2 complexes. At
this juncture, we do not know if AGE-MD2 complexes were
formed during transit in the blood or released by tissues or circulating cells. Nonetheless, such elevated levels of pre-formed
AGE-MD2 in circulation and tissues under diabetic conditions
suggest that this could be one reason why TLR4 was predominantly activated by AGE.
One of the biggest unanswered question in our study is the
mode by which AGE products bind to MD2. We attempted to
explore the potential binding mode using a combination of cellbased and cell-free assays. Until now, only the structure of LPS-
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MD2 complex has been reported by crystallography44. To gain
some insight into how AGE products may interact with MD2, we
conducted competition studies using LPS in H9C2 cells. Using a
functionally inactive LPS (Rhodobacter sphaeroides LPS, RS-LPS)
which binds to MD245, we found that HG-induced MD2-TLR4
complex formation was suppressed by ~50% by RS-LPS (Supplementary Fig. 29a). Furthermore, HG partially displaced H9C2
cell surface-bound FITC-labeled LPS (Supplementary Fig. 29b).
The ability of HG to partially compete with LPS binding suggests
that AGE products may share some common binding sites on
MD2 with LPS. However, this notion needs to accompany a
cautionary statement. Considering that AGE products are highly
heterogenous in composition, the exact binding site(s) or binding
modes of AGE products with MD2 will be highly challenging to
delineate. We know that different AGE products may be generated depending on the glucose concentration used, the reacting
process and glycation duration46. Experimental studies also show
that glucose- and glycolaldehyde-modiﬁed BSA is signiﬁcantly
different compared with glyoxal- and methylglyoxal-modiﬁed
BSA, in exhibiting ﬂuorescence patterns, CML content, and
uptake patterns in macrophages30. Considering all of these variables, it is plausible that MD2 acts as a scavenger co-receptor and
interacts with various modiﬁed/altered proteins with different
afﬁnities. In support of this idea is our recent discovery that MD2
binds to saturated fatty acids and oxidized lipoproteins to initiate
TLR4 signaling23,25. Future studies aimed at determining whether
ligands with different afﬁnities induce different intracellular signaling arms of TLR4 and when signaling thresholds are met will
greatly enhance our understanding.
It is important to point out a few limitations of our study. First,
we are unable to conclusively rule out the involvement of MGOand CML-modiﬁed proteins. We show that MGO and CML levels
in vitro and in vivo, detected using published methods, are not
increased at the time points examined. In addition, stimulation with
MGO-BSA and CML-BSA could not activate MD2/TLR4 proinﬂammatory response in cells. Further studies are certainly needed
to fully understand the in vivo pathways of AGE formation in the
extracellular and intracellular milieu, as well as identiﬁcation of the
proteins, lipids or nucleotides glycated, since glycated molecules are
physiologically impaired34,47. Similarly, it is important to understand that clinical diabetic cardiomyopathy takes years to develop.
Experimentally, however, acute or short-term exposure to HG is
enough to generate the readout, which may not unmask all AGE
moieties involved. Second, due to the limited number of samples
from diabetic subjects, we were unable to complete the full spectrum of analyses that were conducted in experimental mice and
cultured cells. Although key readouts were conﬁrmed in serum and
cell samples from diabetic subjects, further studies in samples from
human diabetic subjects would be important.
In summary, the following key ﬁndings support an AGEactivated MD2-TLR4 pathogenic mechanism as a central driving
force behind inﬂammatory myocardial injury in diabetes: (1) HG
was associated with elevated AGE and AGE-MD2 complexes in
serum and myocardial tissue; (2) diabetic human subjects and
mice showed upregulated MD2 and TLR4 levels; (3) AGE products bound directly to MD2 and activated MD2-TLR4 signaling;
(4) MD2 knockout or pharmacological inhibition effectively
blocked diabetes-induced NF-κB/MAPK activation along with
upregulation of inﬂammatory factors. These ﬁndings provide
mechanistic insight in which AGE-activated MD2-TLR4 orchestrates adverse cardiac tissue remodeling in diabetes, and underscore MD2 as a potential target for DCM.
Methods
Reagents. D-glucose, mannitol, lipopolysaccharide (LPS, from Salmonella typhosa),
ﬂuorescein isothiocyanate-conjugated LPS (FITC-LPS, from E. coli 055:B5),
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Rhodobacter sphaeroides LPS (RS-LPS), DAPI, 2-DG, phalloidin, Polymyxin B, and
streptozotocin (STZ) were purchased from Sigma (St. Louis, MO). Recombinant
human MD2 (rhMD2) protein was purchased from R&D Systems (Minneapolis, MN,
USA). Glucose-derived AGE-modiﬁed BSA (AGE-BSA) with a purity >98% was
purchased from BioVision Incorporated (Cat # 2223; Milpitas, CA). Lots used in the
study had a reported endotoxin level <0.1 EU/µg. Endotoxin contamination was
veriﬁed through Chromogenic TAL Endpoint Assay Kit (Cat # EC64405, Bioendo
Technology Co., LTD, Xiamen, China), before using AGE-BSA in any experiments.
CML-BSA was purchased from Cayman Chemicals (Cat # 22972; Ann Arbor, MI).
MGO-BSA was purchased from StressMarq Biosciences Inc (Cat #SPR-208B; Victoria, BC, Canada). Glycolytic function in cells was measured by Agilent Seahorse XF
Glycolysis Stress Test Kit (Agilent Technologies Co. Ltd, Beijing, China).
Anti-GAPDH (Clone: G-9, cat no. sc-365062), anti-IκBα (Clone: H-4, cat no.
sc-1643), anti-MyD88 (Clone: E-11, cat no. sc-74532), anti-ERK1/2 (Clone: C-9,
cat no. sc-514302), anti-p-ERK1/2 (Clone: 12D4, cat no. sc-81492), anti-F4/80
(Clone: C-7, cat no. sc-377009), anti-TGF-β (Clone: 3C11, cat no. sc-130348), antiCol 1 (cat no. sc-59772), anti-TLR4 (Clone: 25, cat no. sc-293072), anti-MD2
(Clone: J-12B, cat no. sc-80183), anti-GLUT4 (Clone: IF8, cat no. sc-53566), antiFlag tags (Clone: G-8, cat no. sc-166384), anti-HA tags (Clone: F-7, cat no. sc7392), anti-ANP (Clone: F-2, cat no. sc-515701), anti-MyHC (Clone: B-5, cat no.
sc-376157), anti-MMP-2 (Clone: 8B4, cat no. sc-13595), anti-MMP-9 (Clone: 6-6B,
cat no. sc-12759), anti-ICAM-1 (Clone: G-5, cat no. sc-8439), anti-VCAM-1
(Clone: E-10, cat no. sc-13160), anti-α-actin (Clone: 1A4, cat no. sc-32251), antiCD68 (Clone: E-11, sc-17832), anti-TNF-α (Clone: 52B83, cat no. sc-52746), and
anti-RAGE (Clone: E-1, cat no. sc-74473) antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibodies directed against JNK (cat no.
9252) and p-JNK (Clone: G9, cat no. 9255), P38 (cat no. 9212) and p-P38 (Clone:
D13E1, cat no. 8690) were obtained from Cell Signaling (Danvers, MA). Anti-AGE
antibody (cat no. ab23722) was obtained from AbCam. Compound L6H21, a
selective MD2 inhibitor, was synthesized, validated, and prepared with a purity of
98.9% as described by us27. Our previous studies have established antiinﬂammatory activities of L6H2127. L6H21 was dissolved in DMSO for in vitro
studies and in 1% sodium carboxyl methyl cellulose (CMC-Na) for in vivo studies.
MGO levels in culture media and tissues were determined as described
previously48. CML levels were measured by CircuLex CML/Nε-Carboxymethyllysine ELISA (cat no. CY-8066; Clinisciences, Nanterre, France).
Cell isolation culture. An embryonic rat heart-derived H9C2 line was obtained
from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China)
and cultured in DMEM (Gibco, Eggenstein, Germany) containing 1 g/L glucose
supplemented with 10% heat-inactivated FBS (Thermo Fisher, Waltham, MA), 100
U/ml of penicillin, and 100 mg/ml of streptomycin. Mouse primary peritoneal
macrophages (MPMs) were isolated from C57BL/6 wild-type mice or MD2−/−
mice as described by us previously23. Primary rat cardiomyocytes were isolated
from Sprague-Dawley (SD) rats as described previously23. Cardiac endothelial and
ﬁbroblasts were isolated from C57BL/6 wild-type mice used the methods described
previously49,50. All cells were cultured and expanded in media containing heatinactivated serum. Where indicated, serum which did not undergo heatinactivation (Thermo Fisher) was used. To determine the effects of high levels of
glucose, cardiomyocytes, H9C2 cells, and MPMs were exposed to 33 mM glucose as
shown by us51,52 and others53,54, with the exception of dose–response studies.
Human subject recruitment. Eight apparently healthy subjects without diabetes,
and seven diabetic subjects without evidence of suppressed ejection fraction (EF%),
and nine diabetic patients with reduced EF% and without the indication of other
cardiac diseases were recruited from the hospital clinic and community, based on an a
priori protocol. All subjects were screened for the echocardiographic exam. DM and
DCM candidates were excluded if they were pregnant, had a self-reported history of
symptomatic micro- or macrovascular complications of diabetes (including nephropathy, neuropathy, retinopathy, peripheral vascular disease, ischemic heart disease,
and stroke) or other signiﬁcant comorbidities including malignancy, renal failure, or
signiﬁcant psychiatric illness. The information of healthy subjects and diabetic
patients are shown in the Supplementary Table 1. Consent was obtained from patients
to disclose age and sex, and location of treatment. Approval for this study was granted
by the Human Research Ethics Committees of Wenzhou Medical University,
Wenzhou, China. All subjects gave written, informed consent to participate in the
study and research was carried out in accordance with the Declaration of Helsinki
(2008) of the World Medical Association. Serum was prepared by centrifugation of
fresh blood samples at 1000 × g for 20 min. About 5 mL of blood was obtained from
each donor using BD Vacutainer tubes containing acid-citrate-dextrose anti-coagulant, solution A (ACD-A; BD Sciences), from which plasma and peripheral blood
mononuclear cell (PBMCs) were isolated.
Animal care and preparation. Male C57BL/6 mice (18–22 g) and male SD rats
(200–220 g) were obtained from the Animal Centre of Wenzhou Medical University
(Wenzhou, China). MD2−/− mice on C57BL/6 background were purchased from
Riken BioResource Center (Tokyo, Japan). Male db/db (C57BLKS/J-leprdb/leprdb)
mice and male db/m littermates were purchased from Model Animal Research Center
of Nanjing University (Nanjing, China). All animals were housed at a constant room
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temperature with a 12:12 h light–dark cycle and fed with a standard rodent diet and
water in the Animal Centre of Wenzhou Medical University. All animals received
humane care according to the National Institutes of Health (USA) guidelines. All
animal care and experimental procedures were approved by the Wenzhou Medical
University Animal Policy and Welfare Committee.
To model cardiac injury in type 1 diabetes, C57BL/6 (WT) and MD2−/−
(MD2KO) mice were made diabetic by a single dose intraperitoneal injection of
streptozotocin (STZ, 100 mg/kg in citrate buffer, pH 4.5). This dose of STZ has
been shown to reliably induce diabetes in C57BL/6 mice55, and validated by our
group51,52. Vehicle control group of mice received the same volume of citrate
buffer. Fasting blood glucose levels were measured starting day 3 using glucometer.
Mice showing fasting glucose levels >12 mM (~216 mg/dL) on 3 consecutive days
were considered diabetic, as outlined previously56. Body weights and fasting
glucose levels were measured in all mice weekly for the duration of the study. The
experimental groups were as follows: non-diabetic WT controls (WT-Con, n = 6),
STZ-induced WT diabetic mice (WT-STZ, n = 7), non-diabetic MD2−/− controls
(MD2KO-Con, n = 6), and STZ-induced MD2−/− diabetic mice (MD2KO-STZ, n
= 7). All other mice were euthanized 16 weeks following the onset of diabetes.
Euthanasia was performed under sodium pentobarbital anesthesia and the blood
was collected for subsequent analyses. Heart tissues were collected and ﬁxed in 4%
paraformaldehyde for pathological analysis and/or snap-frozen in liquid nitrogen
for gene and protein expression analyses. Systolic and diastolic cardiac function
was determined non-invasively by transthoracic echocardiography in anesthetized
mice, 1 day before the sacriﬁce. Mice were anesthetized using isoﬂurane and
echocardiography was performed by SONOS 5500 ultrasound (Philips Electronics,
Amsterdam, Netherlands) with a 15-MHz linear array ultrasound transducer.
To examine cardiac MD2-TLR4 activation in a type 2 model of diabetes, we
utilized 8-week-old male db/db mice. db/m littermates were used as controls. Male
db/db mice (n = 5) and db/m mice (n = 5) were fed the standard rodent diet for
16 weeks. Mice were then euthanized under sodium pentobarbital anesthesia and
the blood and heart tissue were collected for subsequent analyses.
Bone marrow transplantation. One week before transplantation, MD2−/− mice
(MD2KO) were put in ﬁlter-top cages and given acidiﬁed water containing neomycin (1.1 mg/L) and polymyxin B sulfate (1000 U/L). One day prior to transplantation, mice were subjected to total body irradiation (6 Gy). For
transplantation, MD2KO mice were injected intravenously with 5 × 106 bone
marrow cells from pools of bone marrow from C57BL/6 (WT) and MD2−/−
(MD2KO) mice. Tail-clip samples and peritoneal macrophages were used for
genotyping and conﬁrmation of reconstitution.
Histology and tissue staining. Heart tissues were ﬁxed in 4% paraformaldehyde,
embedded in parafﬁn and sectioned at 5-µm thickness. After dehydration, sections
were stained with hematoxylin and eosin (H&E). Stained sections were evaluated
for general histopathological damage using light microscopy (Nikon, Japan).
Cardiomyocyte size was evaluated in cross-sections of heart tissues. Additional
parafﬁn sections were stained with Masson’s Trichrome (Beyotime Biotech, Nantong, China) and Sirius Red (Beyotime Biotech, Nantong, China) to assess cardiac
ﬁbrosis. The stained sections were viewed under a light microscope (Nikon, Japan).
Parafﬁn sections were also used to perform immunohistochemistry for TNF-α and
CD68 using routine techniques. Immunoreactivity was detected by
diaminobenzidine (DAB).
For ﬂuorescence staining, harvested mouse hearts were embedded in OCT
compound, and cut into 5-μm-thick sections. Sections were incubated with
primary mouse antibodies directed against MD2, and α-actin or F4/80 in a
humidiﬁed chamber at 4 °C overnight. The sections were subsequently incubated
with anti-mouse and anti-rabbit secondary antibodies for 1 h in the dark.
Enzyme-link immunosorbent methods. Pro-inﬂammatory cytokines TNF-α and
IL-6, and AGE products in cell culture medium, homogenized mouse heart tissue,
or serum were determined using commercially available ELISA kits. ELISA for
TNFα and IL-6 were from eBioscience (San Diego, CA). ELISA for human AGE
(ml-024019) and mouse AGE (ml-002154) were from mlbio (Shanghai Enzymelinked Biotech, Shanghai, China). Total amount of TNFα, IL-6, or AGE in the cell
culture medium was normalized to the total amount of protein in the viable cell
pellets. Experiments were performed in triplicates.
To detect AGE-MD2 complexes in serum samples, a sandwich ELISA was used.
Anti-human or anti-mouse AGE antibodies (Shanghai Enzyme-linked Biotech,
Shanghai, China) were pre-coated onto 96-well plates. Serum samples were added
and incubated for 1 h at 37 °C. Plates were washed six times and incubated with
anti-human MD2 antibody (Abcam) or anti-mouse MD2 antibody (Abcam) for 1 h
at 37 °C. Antigen-antibody complexes were washed six times and incubated with
peroxidase-conjugated secondary antibody (Yeasen Bio) for 1 h at 37 °C. TMB
substrate was added, followed by a stop solution (mlbio), and the horseradish
peroxidase activity was measured in M5 microplate reader at 450 nm. Values are
reported in optical density units.
To determine binding between AGE-BSA and recombinant human (rh) MD2,
individual protein solutions or mixed solutions at 1:1 or 1:0.05 ratios were loaded
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on plates coated with bovine AGE antibody. Plates from commercially available
bovine AGE ELISA (ml-003305; mlbio) were used. Plates were washed and
incubated with anti-human MD2 antibody (Abcam) for 1 h at 37 °C. Detection was
performed as described above.
Gene silencing. MD2, TLR4, and GLUT4 were silenced in H9C2 cells through
siRNA. Rat MD2 siRNA (5ʹ-TATTAAATACTGTTGC-3ʹ), rat TLR4 siRNA (5ʹTTCTAACTTCCCTCCT-3ʹ), and rat GLUT4 siRNA (5ʹ-CAGAGCUACAAUGCAACUUTT-3ʹ) were purchased from Gene Pharma Co. Ltd. (Shanghai,
China). Negative control transfections included scrambled siRNA sequences.
RAGE in H9C2 cells was silenced by transfecting cells with plasmids encoding
RAGE shRNA (Sailan Biotech, Hangzhou, China). All transfections were carried
out using LipofectAMINE™ 2000 (Invitrogen, Carlsbad, California). Knockdown of
genes in the transfected cells was conﬁrmed by western blot analysis.
Western blot and immunoprecipitation. Collected cells or homogenized heart
tissues were lysed and protein concentration determined by the Bradford assay.
Lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and electro-transferred to a nitrocellulose membrane. The membranes
were blocked for 1.5 h at room temperature in Tris-buffered saline (pH 7.6) containing 0.05% Tween 20 and 5% non-fat dry milk. Primary antibody incubations
were carried out at 4 °C overnight. Secondary antibodies were applied for 1 h at
room temperature. Immunoreactivity was visualized using enhanced chemiluminescence reagents (Bio-Rad Laboratories, Hercules, CA), and quantiﬁed using
Image J analysis software version 1.38e (NIH, Bethesda, MD, USA). Values were
normalized to respective protein controls.
Protein complexes were evaluated by co-immunoprecipitation combined with
immunoblotting. Cell lysates (300–500 μg) were incubated with precipitating
antibody at 4 °C overnight, and immunoprecipitated with protein A + G-sepharose
beads with shaking at room temperature for 2 h. The protein–bead complexes were
washed ﬁve times with PBS, electrophoresed, transferred to PVDF membranes and
detected with immunoblotting antibody.
Real-time quantitative PCR. Cells and heart tissues were homogenized in TRIZOL (Invitrogen, Carlsbad, CA). Both reverse transcription and quantitative PCR
(qPCR) were carried out using a two-step M-MLV Platinum SYBR Green qPCR
SuperMix-UDG kit (Invitrogen, Carlsbad, CA). Eppendorf Mastercycler® Ep
Realplex detection system (Eppendorf, Hamburg, Germany) was used for qPCR
analysis. The primers of target genes are listed in the Supplementary Table 2 and
were obtained from Invitrogen (Shanghai, China). The amount of each gene was
determined and normalized to the amount of β-actin.
Isothermal titration calorimetry (ITC) assay. The interactions between MD2
and AGE products or glucose were carried out on a Nano-ITC instrument (TA
instruments, New Castle, DE) at 25 °C. The proteins were dissolved in ddH2O.
AGE-BSA (1 μM) or rhMD2 (10 μM) were added to the calorimetric reaction cell,
and an injection syringe was ﬁlled with MD2 protein solution (5 μM) or D-glucose
(100 μM), respectively, with stirring at 18 × g. Each titration experiment was performed with 20 injections of 2.5 μL at 300 s equilibration intervals. The heat of
dilution for AGE-BSA or MD2 protein was determined by titrating it into the
ddH2O. Data were ﬁtted with the NanoAnalyze software package (TA Instruments). The total heat exchanged during each injection of MD2 to
AGE-BSA or glucose to MD2 was ﬁtted to an independent model with variable
parameters.
Statistical analysis. All experiments were randomized and blinded. In vitro
experiments were repeated at least three times. Data were presented as means ±
SEM, and individual data points are plotted in ﬁgures. The statistical signiﬁcance
of differences between groups was obtained by the unpaired student’s t-test or
one-way ANOVA followed by Tukey’s post hoc test in GraphPad Pro5.0
(GraphPad, San Diego, CA). Details of statistical testing can be found in the
ﬁgure legends and in the source data ﬁle. Differences were considered to be
signiﬁcant at p < 0.05.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this paper.

Data availability
The source data underlying Figs. 1–7 in the article and Supplementary Figs. 1–29 in the
Supplementary Information are provided as a Source Data ﬁle. All other data are
included within the article or Supplementary Information or are available from the
corresponding author upon reasonable request.
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